Recursion extends its runway to 2029 as its lead drug shows durable benefit

The quarter in numbers

Recursion Pharmaceuticals reported third-quarter 2026 financial results in which total revenue, consisting primarily of revenue from collaboration agreements, was $18.6 million, and net loss was $119.0 million. Expected cash runway was extended into 2029, including proceeds from the October 2026 follow-on offering, according to the company's results announcement. m:…2486

The company's 8-K filing discloses the same quarter alongside pipeline progress and a board appointment, and reiterates 2026 cash operating expense guidance of less than $375 million. The filing also records that Sanofi has exercised an option on a dual-targeting small molecule candidate from the collaboration. m:…5879

The results announcement adds that Sanofi's option exercise covers the first development candidate from the Recursion collaboration, and that Genentech exercised the first Validated Target Option under the companies' neuroscience collaboration. Those two partner actions are the external validation in the quarter: both are decisions by collaborators to advance programmes rather than Recursion's own assessment of its pipeline. m:…2486

The lead programme

New Phase 2 data for REC-4881, an investigational oral MEK1/2 inhibitor for familial adenomatous polyposis, were presented at the CGA-IGC annual meeting, from the Phase 1b/2 TUPELO trial. After 12 weeks of treatment, patients achieved a 47% median reduction in total polyp burden, and 12 weeks after stopping treatment, 85% of evaluable patients remained below baseline polyp burden, the company says. m:…5435

Nearly one in two patients in the upper gastrointestinal tract achieved polyp burden reductions of at least 65%, and six of eight patients with polyps larger than 5 millimetres at baseline had reductions in the number of those polyps after 12 weeks. The highest-grade treatment-related adverse event was Grade 1 or 2, and Grade 3 in four patients, or 15%, and no Grade 4 or 5 events reported. m:…5435

Familial adenomatous polyposis is a rare inherited disease affecting more than 50,000 patients in the US and the five largest European markets, with no approved pharmacologic therapies, the company says, and REC-4881 is described as a potential first-in-class oral therapy. The company anticipates initiating a registrational trial in the second half of 2027, and collaborated with Amsterdam University Medical Center to analyse a registry of approximately 200 patients with the disease. m:…5435

The earlier-stage pipeline also moved: REC-1245 showed a 91.7% disease control rate, at doses of at least 45 milligrams, with one unconfirmed partial response, according to the results announcement. That figure comes from a small population and an expansion cohort the company is still monitoring, so it is a signal to track rather than a conclusion. m:…2486

New chair, same board continuity

Recursion appointed Fred Hassan as Chair of the Board, effective October 31, 2026. Hassan has more than four decades in the pharmaceutical industry, previously serving as chair and chief executive of Schering-Plough from 2003 to 2009 and of Pharmacia from 2001 to 2003, and currently serving as lead independent director of BridgeBio Pharma and executive chair of Norstella, as well as a director at Warburg Pincus, the company says. m:…0739

Outgoing chair Rob Hershberg will remain on the board, continuing to contribute as a physician-scientist, which preserves scientific continuity while the chair role changes. The appointment, the partner option exercises and the extended runway together describe a company positioning for the expensive phase of drug development: registrational trials, partner-funded programmes and a cash position intended to last into 2029. m:…0739 m:…2486